MedTrace Logo

Biomarker-based Prognostic Assessment

NCT04044066 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 10000

Last updated 2020-07-07

No results posted yet for this study

Summary

Coronary artery disease (including stable angina and acute coronary disease) remains the leading mortality and morbidity worldwide. Improvement in biomarker, imaging research have led to new predictors for the prognosis, which may have great clinical value in the current era of personalized medicine. However, there is no available biomarker-based prediction rule for risk assessment of adverse events in patients with stable angina and acute coronary disease. Therefore, we aim to develop and validate a new biomarker-based risk model to improve the prognostication of adverse events (e.g. ischemic and bleeding events ) in the patient population.

Conditions

  • Acute Coronary Syndrome
  • Stable Angina

Interventions

BIOLOGICAL

Plasma biomarker

New emerging plasma biomarkers carrying prognositic information

Sponsors & Collaborators

  • Peking University Third Hospital

    collaborator OTHER

  • Chinese PLA General Hospital Hospital

    collaborator UNKNOWN

  • Peking University First Hospital

    collaborator OTHER

  • Central Hospital of Zibo

    collaborator OTHER

  • Qilu Hospital of Shandong University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-09
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04044066 on ClinicalTrials.gov